Drug Trial Radar · NCT04434092
A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
210
Actual
Start
Oct 8, 2020
Primary completion
Nov 16, 2022
Study completion Apr 18, 2027
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Chugai Pharmaceutical
- First posted
- Jun 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study designed to evaluate the non-inferiority of crovalimab compared with eculizumab in participants with PNH who have not been previously treated with complement inhibitor therapy.
Conditions
- Paroxysmal Nocturnal Hemoglobinuria
Interventions
CrovalimabDrug
Dosing depends on body weight. Participants will be dosed as follows: * 5 kg to \< 12 kg: 100 mg IV on Week 1 Day 1 (W1D1); 85 mg SC on Week 1 Day 2 (W1D2) and Q2W from Week 3 until end of study * 12 kg to \< 20 kg: 200 mg IV on W1D1; 85 mg SC on W1D2, Weeks 2, 3 and 4; 170 mg SC, Q2W from Week 5 until end of study * 20 kg to \< 30 kg: 300 mg IV on W1D1; 85 mg SC on W1D2, Weeks 2, 3 and 4; 340 mg SC, Q4W from Week 5 until end of study * 30 kg to \< 40 kg: 400 mg IV on W1D1; 170 mg SC on W1D2, Weeks 2, 3 and 4; 510 mg SC, Q4W from Week 5 until end of study * 40 kg to \< 100 kg: 1000 mg IV on W1D1; 340 mg SC W1D2, Weeks 2, 3 and 4; 680 mg SC, Q4W from Week 5 until end of study * 100 kg: 1500 mg IV on W1D1; 340 mg SC W1D2, Weeks 2, 3 and 4; 1020 mg SC, Q4W from Week 5 until end of study.
EculizumabDrug
Eculizumab will be administered as specified in the respective arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Transfusion Avoidance (TA)Time frame: Baseline to Week 25
- Percentage of Participants With Hemolysis Control Measured by LDHTime frame: Week 5 to Week 25
Locations
63 sites in 23 countries. Site status is shown where the registry gives one.
Organizacion Medica de Investigacion (OMI)
Ciudad Autonoma Buenos Aires, Argentina
Beneficencia Portuguesa de Sao Paulo
São Paulo, Brazil
*X*CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia
Santo André, São Paulo, Brazil
Peking Union Medical College Hospital
Beijing, China
Nanfang Hospital, Southern Medical University
Guangzhou, China
The First Affiliated Hospital, Zhejiang University
Hangzhou, China
Jiangsu Province Hospital
Nanjing, China
Affiliated Hospital of Nantong University
Nantong, China
Huashan Hospital, Fudan University
Shanghai, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China
Hopital Claude Huriez - CHU Lille
Lille, France
Centre Hospitalier Lyon Sud
Pierre-Bnite, Rhone, France
Universitaetsklinkm
Essen, Germany
Universitaetsklinikum Ulm
Ulm, Germany
General Hospital of Thessaloniki G. Papanikolaou
Thessaloniki, Greece
Sapporo Medical University Hospital
Hokkaido, Japan
University of Tsukuba Hospital
Ibaraki, Japan
NTT Medical Center Tokyo
Tokyo, Japan
Tokyo Medical University Hospital
Tokyo, Japan
Vilnius University Hospital Santariskiu Clinics, Public Institution
Vilnius, Lithuania
Hospital Tengku Ampuan Afzan
Kuantan, Malaysia
Hospital Raja Permaisuri Bainun
Ipoh, Perak, Malaysia
Hospital Pulau Pinang
George Town, Pulau Pinang, Malaysia
Hospital Ampang
Ampang, Selangor, Malaysia
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Mexico City, Mexico CITY (federal District), Mexico
Global Trial Research Center S.A. de C.V.
Monterrey, Nuevo León, Mexico
Amsterdam UMC, Locatie AMC
Amsterdam, Netherlands
Mary Mediatrix Medical Center
Lipa City, Philippines
Philippine General Hospital
Manila, Philippines
St Lukes Medical Center
Quezon, Philippines
Szpital Uniwersytecki nr2 im. dr J. Biziela
Bydgoszcz, Poland
Uniwersyteckie Centrum Kliniczne
Gdansk, Poland
Samodzielny Publiczny Szpital Kliniczny nr 1
Lublin, Poland
Pratia Poznan
Skórzewo, Poland
MTZ Clinical Research Powered by Pratia
Warsaw, Poland
Centro Hospitalar do Baixo Vouga E.P.E. - Hospital de Aveiro
Aveiro, Portugal
Instituto Portugues Oncologia de Lisboa Francisco Gentil EPE
Lisbon, Portugal
Centro Hospitalar do Porto - Hospital de Santo António
Porto, Portugal
Spitalul Universitar de Urgenta Bucuresti
Bucharest, Romania
Spitalul Clinic Municipal Filantropia Craiova
Craiova, Romania
Showing 40 of 63 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.